We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...

More than half of myeloma patients surveyed said they experienced daily pain, and more than three-quarters reported a history of opioid use. Many patients with multiple myeloma experience ...

Patients with multiple myeloma often develop bone lesions resulting in skeletal-related events (SREs), such as spinal cord compression, vertebral collapse, pathologic fractures and bone pain. Bone ...

Despite advancements in the treatment of this disease, MM remains incurable and often leads to complications, such as multiple myeloma bone disease (MMBD). Surgical intervention is frequently ...

Bone disease is a hallmark of multiple myeloma (MM), associated with bone pain, pathological fractures requiring surgery and/or radiation to bone, spinal cord compression and hypercalcemia.

Her husband, Todd, was experiencing nagging back pain after ... After a bone marrow biopsy and blood tests, he was diagnosed with a rare, incurable cancer called multiple myeloma, which affects ...

could reshape how physicians address fatigue and pain in multiple myeloma patients. Following is a transcript of her remarks: I presented a study about 6-month exercise interventions in multiple ...

DARZALEX FASPRO ® is a prescription medicine used to treat adult patients with multiple myeloma: · in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly ...

In 2003, bortezomib (Velcade; Millenium) became the first drug approved by the US FDA for use in patients with relapsed or refractory MM. Bortezomib, given intravenously, inhibits the 26S ...

Forty-eight patients with multiple myeloma ... of multiple myeloma (such as serum and urine paraprotein levels, soft-tissue plasmacytomas, osteolytic lesions and bone-marrow plasmacytosis).

Strengthening bones affected by metastases, which reduces pain and fracture risk Improving progression-free survival and ... denosumab was better than Zometa in reducing the risk of fractures related ...